+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 11 Actively Recruiting clinical trials

P

Actively Recruiting

Researchers are evaluating AZD0780, an oral PCSK9 inhibitor, in a phase 3 randomized, double-blind, placebo-controlled study to assess its effect on reducing major adverse cardiovascular events in patients with established atherosclerotic cardiovascular disease ASCVD or those at high risk for a first ASCVD event. The study compares AZD0780 with a placebo and is event-driven, focusing on time to first cardiovascular events over approximately 54 months. Participants will be randomly assigned to receive either oral AZD0780 once daily or a matching placebo once daily. The study treatment continues from randomization until the primary analysis censoring date, followed by a study closure visit which marks the final visit for each participant. Background lipid-lowering therapy is maintained and expected to achieve significant LDL cholesterol reduction. The study design includes parallel treatment groups with quadruple masking to ensure unbiased results. During the study, participants attend regular visits for monitoring and assessments over a period that can last up to about 54 months. Researchers will measure the time to first major cardiovascular events including heart attack, stroke, urgent coronary revascularization, cardiovascular death, and other related outcomes. Safety and efficacy are carefully monitored through clinical evaluations, laboratory tests, and patient follow-up until study completion.

Age: 18Years +All GendersPhase 3
1452 locations
P

Actively Recruiting

Researchers are evaluating a drug called sigvotatug vedotin SGN-B6A alone and in combination with pembrolizumab, with or without chemotherapy, to assess its safety and effects in people with advanced solid tumors. This Phase 1 study aims to determine the side effects and whether sigvotatug vedotin works to treat various solid tumors including lung, head and neck, breast, esophageal, skin, pancreatic, bladder, cervical, gastric, and ovarian cancers. The study is divided into four parts to explore dosage, safety, and combination treatments. Participants may receive sigvotatug vedotin alone or combined with pembrolizumab, sometimes alongside chemotherapy drugs carboplatin or cisplatin, depending on the study part. Part A focuses on finding the right dose of sigvotatug vedotin. Part B uses this dose to further test safety and effectiveness. Parts C and D study the drug combined with pembrolizumab and possibly chemotherapy in different tumor types and treatment settings, including people who have not previously received treatment. Treatments are given intravenously, with pembrolizumab administered every 3 or 6 weeks and chemotherapy every 3 weeks. During the study, participants undergo tumor biopsies, clinical evaluations, and monitoring for side effects, including blood tests and safety assessments. Researchers track adverse events, lab abnormalities, and dose-limiting toxicities up to 30-37 days after treatment, with some follow-up extending up to 3 years. They also measure tumor response using standard criteria and monitor survival and drug levels in the body. Participants will have regular visits for treatment and assessments throughout the study duration, which may last several years.

Age: 18Years +All GendersPhase 1
158 locations
E

Actively Recruiting

Researchers are evaluating the safety and effectiveness of GDC-4198 alone and combined with giredestrant compared to abemaciclib plus giredestrant in people with locally advanced or metastatic estrogen receptor-positive ER, HER2-negative breast cancer. This study includes two parts Phase Ib to assess safety and how the body processes GDC-4198, and Phase II to compare the activity and safety of the two treatment combinations. Participants benefiting from GDC-4198 in a previous study may continue with this treatment. Participants receive GDC-4198 by mouth either alone or with giredestrant daily in 28-day cycles until unacceptable side effects, disease progression, or loss of benefit. Different dosing levels of GDC-4198 combined with giredestrant are studied, and others receive abemaciclib with giredestrant. Those from the earlier study continuing treatment keep their current dose of GDC-4198. During the study, participants will be regularly monitored for side effects and treatment impact, including disease progression and response rates. Researchers will track adverse events, dose-limiting toxicities, progression-free survival, and overall survival for up to 36 months. Assessments include safety evaluations, pharmacokinetics of GDC-4198, and measuring clinical benefit throughout the trial period.

Age: 18Years +All GendersPhase 1Phase 2
77 locations
E

Actively Recruiting

Researchers are evaluating the drug VIM0423 in adults with Parkinsons disease who experience tremors that do not respond well to dopaminergic therapy. The study aims to determine if VIM0423 improves tremor symptoms, is well tolerated, and enhances daily function and quality of life. This Phase 2, multicenter, randomized, placebo-controlled trial will enroll up to 80 participants with Parkinsons tremor, a symptom that affects many and is often the most troubling for patients. Participants are divided into two groups Cohort 1 includes those on stable dopaminergic therapy with residual tremor, and Cohort 2 includes those who have never used dopaminergic therapies. Both cohorts are randomized to receive either VIM0423 or matching placebo, with doses up to five pills once daily for seven weeks. The study is triple-blinded, meaning neither participants nor investigators know the assigned treatment. The total participation lasts up to 12 weeks, including screening, treatment with tapering, and safety follow-up. During the study, participants attend six in-person visits for assessments including clinical evaluations, lab tests, and EKGs. They will wear a device to monitor tremor and complete self-assessments of tremor impact on daily activities. The primary outcome is change in Parkinsons disease symptoms measured by the Movement Disorder Society Unified Parkinsons Disease Rating Scale from baseline to Week 6. Secondary measures include clinician and patient global impressions, tremor-related daily living scales, and sleep assessments. Safety and adverse events are closely monitored throughout.

Age: 18Years - 65YearsAll GendersPhase 2
30 locations
R

Actively Recruiting

Researchers are evaluating the treatment of older adults aged 75 and above with early-stage cutaneous melanoma. The study compares the effectiveness of wide local excision WLE alone to the usual care of WLE combined with sentinel lymph node SLN biopsy. The main goal is to see if the less invasive WLE alone can provide similar results in preventing melanoma recurrence. This phase III trial also aims to assess patient-reported outcomes and the impact of geriatric assessments on treatment results. Participants are randomly assigned to one of two groups one group receives WLE plus SLN biopsy, and the other group receives WLE alone. Both groups may undergo surveillance of the lymph node area and receive additional treatments called adjuvant therapies if needed. Throughout the study, participants may have imaging tests such as computed tomography CT, positron emission tomography PETCT, or ultrasound. After initial treatment, patients are monitored closely with regular follow-ups. During the study, participants will be followed every four months for two years and then every six months up to five years after randomization. Researchers will collect data on recurrence-free survival, overall survival, melanoma-specific survival, safety, and patient quality of life. The study also involves comprehensive geriatric assessments and questionnaires to evaluate physical and functional status. These measures will help develop tools to predict risks and guide future surgical decisions for older adults with melanoma.

Age: 75Years +All GendersPhase 3
181 locations
E

Actively Recruiting

Researchers are evaluating the use of a cellular, acellular, matrix-like product called Amnio-Maxx4 Dual Layer Amnion Patch alongside the Standard of Care SOC compared to SOC alone for closing nonhealing diabetic foot ulcers DFUs. This Phase 4 randomized controlled trial focuses on adult patients with chronic DFUs to better understand how Amnio-Maxx may affect healing rates. Participants will receive either the Standard of Care, which includes cleansing, debridement, wound documentation, and off-loading, or the Standard of Care plus the application of the Amnio-Maxx Dual Layer Amnion Patch. The study uses random assignment without masking. Treatments are applied during study visits, and the ulcer is carefully monitored for closure and healing progress. During the 12-week trial, participants will undergo assessments including ulcer measurements to evaluate complete closure and percentage area reduction. Pain related to the ulcer will be tracked using the Numeric Pain Rating Scale. Researchers will also monitor adverse events throughout the study. Participants must follow treatment protocols and attend regular visits to support accurate evaluation of outcomes related to healing diabetic foot ulcers.

Age: 18Years +All GendersPhase 4
8 locations
S

Actively Recruiting

Researchers are evaluating the safety and effectiveness of nipocalimab compared to a placebo in adults with chronic inflammatory demyelinating polyneuropathy CIDP who initially respond to nipocalimab treatment. The study focuses on delaying relapse in this population and involves multiple phases and stages to assess the treatments impact. This trial is sponsored by Janssen Research & Development, LLC and includes adults diagnosed with CIDP according to specific criteria. Participants first enter Stage A, where they receive an initial loading dose of nipocalimab by intravenous infusion on Day 1, followed by doses every two weeks from Week 2 to Week 12. Those who show clinical improvement proceed to Stage B, a double-blind phase where they are randomly assigned to receive either nipocalimab or placebo infusions every two weeks for up to 52 weeks. Following Stage B, participants may join an open-label extension phase to continue receiving nipocalimab every two weeks until two years after the drugs marketing authorization in their country or until it becomes commercially available. Throughout the study, participants undergo regular assessments including evaluations of disability, muscle strength, grip strength, and disease activity scores. Researchers monitor for relapses, adverse events, and changes in laboratory and clinical parameters. The primary outcome measures include the time to first relapse during Stage B, with additional secondary outcomes assessing clinical improvements, safety, and immunologic responses. Total participation may last several years depending on extension phase involvement.

Age: 18Years +All GendersPhase 2Phase 3
120 locations
M

Actively Recruiting

Researchers are studying Medicare beneficiaries with Lumbar Spinal Stenosis LSS and Neurogenic Claudication NC to compare outcomes after two different procedures MILD Percutaneous Image-Guided Lumbar Decompression and Interspinous Process Decompression IPD. This observational study tracks patients treated since January 1, 2017, evaluating the rates of surgical and minimally invasive interventions as well as any harms related to these procedures over 24 months. The study uses Medicare claims data and does not require prior patient consent or IRB oversight. The study includes two groups of patients those who received the MILD procedure, involving partial decompression under image guidance by removing tissue and bone at the affected spinal level, and those who underwent IPD, a device-based decompression technique. Both groups are observed through Medicare data for two years after their initial procedure to assess the need for further surgeries or interventions and to monitor for any complications. Participants are followed for 24 months after their index procedure using Medicare claims data. Researchers monitor the rates of harms associated with the initial treatment and the frequency of additional surgical or minimally invasive interventions. Since this is an observational study, data collection relies on existing Medicare records without direct patient involvement, and the study will continue enrolling patients until the sponsor stops it.

Age: 18Years +All Genders
2393 locations
R

Actively Recruiting

Researchers are evaluating overall survival in patients with advanced metastatic or locally recurrent breast cancer who have no approved alternative therapies available. This Phase 3, multicenter, randomized, open-label study compares the Bria-IMT regimen combined with the checkpoint inhibitor Retifanlimab against treatment chosen by patients or physicians, known as Treatment of Physicians Choice TPC. The study also investigates the activity of the Bria-IMT regimen alone compared to its combination with Retifanlimab. Participants are initially randomized into three groups Bria-IMT regimen plus Retifanlimab combination therapy, TPC, and Bria-IMT regimen alone monotherapy. After enrolling the first 150 patients, the monotherapy group will be discontinued, and those patients may switch to combination therapy. The Bria-IMT regimen includes cyclophosphamide administered 2-3 days before SV-BR-1-GM given intradermally in four inoculations, followed by checkpoint inhibitor infusion plus interferon injections at inoculation sites over three days. Treatment cycles repeat every three weeks, while TPC is given per standard care at each site. Imaging assessments are conducted every six weeks twice, then every eight weeks thereafter unless disease progression or safety issues occur. During the study, participants will have regular therapy cycles and imaging assessments to monitor disease progression. Researchers will evaluate outcomes such as overall survival up to 60 months, progression-free survival, clinical benefit rate, overall response rate, quality of life, and central nervous system event-free survival. Safety and treatment effects will be closely monitored throughout the trial, which is expected to complete by June 2028.

Age: 18Years +All GendersPhase 3
79 locations
A

Actively Recruiting

Researchers are studying a new medicine called PF-08634404 to see how well it works in adults with metastatic colorectal cancer, which is cancer that has spread to other parts of the body. The study compares PF-08634404 combined with approved chemotherapy to an approved medicine called Bevacizumab combined with chemotherapy. The goal is to understand if the new medicine can improve outcomes for people whose cancer has spread or returned after previous treatments. Participants are randomly assigned to one of two treatment groups. One group receives PF-08634404 with chemotherapy, and the other group receives Bevacizumab with chemotherapy. All medicines are given through intravenous IV infusions at a clinical site. Treatment is given in cycles, and participants may continue treatment as long as it is helping and side effects are manageable. After treatment ends, participants return for a final visit around 30 to 37 days later. During the study, participants have regular visits for treatment, health checks, and tests. Follow-up continues every 12 weeks through phone, in-person visits, or health record reviews to monitor health status and any new treatments. Researchers will measure outcomes such as progression-free survival, overall survival, response rates, side effects, quality of life, and drug levels. The study is expected to last about 33 months per participant.

Age: 18Years +All GendersPhase 3
372 locations

1-10 of 11

1